ALSO NOTED: Indian pharmas wring hands over rising rupee; MAP Pharma sets IPO price

> Fearing a loss in export revenues, Indian drug makers want their government to help shield them from recent gains in the value of the rupee. Report

> MAP Pharmaceuticals has set its IPO target at between $14 and $16 per share, planning to sell 5 million shares for a market cap of up to $308 million. Report

> GlaxoSmithKline and Taisho Pharmaceutical will jointly roll out an over-the-counter herpes remedy in Japan as soon as next month. Report

> The FDA gave its blessing to Novo Nordisk's Norditropin drug for use in girls with short stature stemming from Turner Syndrome. Release

And Finally... Resistant bacteria are stubborn little critters especially in intensive care units, and Australian scientists are using pigs to figure out why. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.